Marinus Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.07.24	Marinus Pharma Says Ganaxolone To Treat Seizures Associated With CDD Approved In China (RTTNews)
17.06.24	Marinus Pharma Says Phase 3 Trial Of IV Ganaxolone In RSE Meets First Co-primary Endpoint (RTTNews)
15.04.24	Marinus Pharma Says RAISE Trial Did Not Meet The Early Stopping Criteria; Stock Dips In Pre-market (RTTNews)
26.04.23	Did You Catch These Biotech High-Flyers Before They Hit New Highs Yesterday? (RTTNews)
22.03.23	Marinus : FDA Grants Orphan Drug Designation To Ganaxolone For Lennox-Gastaut Syndrome Treatment (RTTNews)
17.11.22	Marinus Pharma Names CEO Scott Braunstein As Chairman (RTTNews)
08.11.22	Pre-market Movers: NRBO, HIMS, OCUP, TRIP, TTWO… (RTTNews)
22.03.22	CLRB To Report WM Trial Data In 2H, DICE On Watch, URGN Sees 46%-67% Revenue Growth In 2022 (RTTNews)
28.02.22	Biotech Stocks Facing FDA Decision In March 2022 (RTTNews)
10.02.22	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Businesswire)
03.02.22	Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update (Businesswire)
14.01.22	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Businesswire)
05.01.22	Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference (Businesswire)
27.12.21	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Businesswire)
03.12.21	Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting (Businesswire)
01.07.21	Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D. (Businesswire)
22.06.21	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
14.06.21	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
11.06.21	Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences (Businesswire)
17.05.21	Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results (Businesswire)
13.05.21	Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call (Businesswire)
07.05.21	Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021 (Businesswire)
28.04.21	Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences (Businesswire)
12.04.21	Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
12.04.21	Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments (Businesswire)
24.03.21	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
24.03.21	Marinus Pharmaceuticals Appoints Dr. Saraswathy (Sara) Nochur to Board of Directors (Businesswire)
09.03.21	Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results (Businesswire)
23.02.21	Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization (Businesswire)
17.02.21	Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences (Businesswire)
12.02.21	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
10.02.21	Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021 (Businesswire)
26.01.21	Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus (Businesswire)
13.01.21	Stock Alert: Marinus Pharmaceuticals Climbs 11% (RTTNews)
06.01.21	Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference (Businesswire)
21.12.20	Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index (Businesswire)
08.12.20	Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock (Businesswire)
08.12.20	Pre-market Movers In Healthcare Sector: NURO, CGIX, MRNS, ARCT… (RTTNews)
07.12.20	Marinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock (Businesswire)
07.12.20	Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update (Businesswire)
07.12.20	Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder (Businesswire)
04.12.20	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.12.20	Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020 (Businesswire)
23.11.20	Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting (Businesswire)
10.11.20	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
09.11.20	Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results (Businesswire)
09.11.20	Marinus Pharmaceuticals Appoints Christy Shafer as Chief Commercial Officer (Businesswire)
20.10.20	Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020 (Businesswire)
19.10.20	Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences (Businesswire)
14.10.20	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	123.40	1.86 %	K V
Alcon	77.56	1.73 %	K V
Logitech Intl	72.72	0.72 %	K V
Kuehne+Nagel Int	210.20	0.67 %	K V
Lonza Grp	529.60	0.57 %	K V
Geberit	523.40	-0.53 %	K V
Swisscom	506.00	-0.59 %	K V
ABB	49.66	-0.60 %	K V
Holcim	88.94	-0.94 %	K V
UBS Group	28.01	-1.20 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Marinus Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten